Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression

Bibliography

• Bobo WV, Shelton RC. Efficacy, safety and tolerability of SymbyaxAR for acute-phase management of treatment-resistant depression. Expert Rev Neurother 2010;10:651-70
   PubMed Web of Science ®Google Scholar
• Angst J, Azorin JM, Bowden CL, Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode. Arch Gen Psychiatry 2011;68:791-9
   PubMed Web of Science ®Google Scholar
• Dubovsky SL, Leonard K, Griswold K, Bipolar disorder is common in depressed primary care patients. Postgrad Med 2011;123:129-33
   PubMed Web of Science ®Google Scholar
• Dubovsky SL. Clinical guide to psychotropic medications. WW Norton, New York; 2005
   Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR, Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22
   PubMed Web of Science ®Google Scholar
• Rybakowski JK. Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. J Affect Disord 2012;136:e13-19
   PubMed Web of Science ®Google Scholar
• Schneck CD, Miklowitz DJ, Miyahara S, The prospective course of rapid cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008;165:370-7
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-33
   PubMed Web of Science ®Google Scholar
• Shi L, Thiebaud P, McCombs JS. The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program. J Affect Disord 2004;82:373-83
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Rosenquist KJ, Ko JY, Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161:163-5
   PubMed Web of Science ®Google Scholar
• Vieta E, Gunther O, Locklear J, Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-49
   PubMed Web of Science ®Google Scholar
• Daly JJ, Prudic J, Devanand DP, ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 2001;3:95-104
   PubMed Web of Science ®Google Scholar
• Grunhaus L, Schreiber S, Dolberg O, Response to ECT in major depression: are there differences between unipolar and bipolar depression? Bipolar Disord 2002;4(Suppl 1):91-3
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the Bolder II study). J Clin Psychopharmacol 2006;26:600-9
   PubMed Web of Science ®Google Scholar
• Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994;55(Suppl):34-44
   PubMedGoogle Scholar
• Croxtall JD, Scott LJ. Olanzapine/fluoxetine. A review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010;24:245-62
   PubMed Web of Science ®Google Scholar
• Barden N. Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 1996;29:12-22
   PubMed Web of Science ®Google Scholar
• Hirsch-Rodriguez E, Imbesi M, Manev R, The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. Med Hypotheses 2007;69:120-4
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90
   PubMed Web of Science ®Google Scholar
• Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
   PubMed Web of Science ®Google Scholar
• Santarelli L, Saxe M, Gross C, Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9
   PubMed Web of Science ®Google Scholar
• Shelton RC. Intracellular mechanisms of antidepressant drug action. Harv Rev Psychiatry 2000;8:161-74
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Smits M, Spence W, Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138-51
   PubMed Web of Science ®Google Scholar
• Tardito D, Perez J, Tiraboschi E, Signaling pathways regulating gene expression, neuroplasticity and neurotrophic mechanisms in the action of antidepressants: a critical review. Pharmacol Rev 2006;58:115-34
   PubMed Web of Science ®Google Scholar
• Marx CE, Shampine LJ, Khisti RT, Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol Biochem Behav 2006;84:609-17
   PubMed Web of Science ®Google Scholar
• Agostinho FR, Reus GZ, Stringari RB, Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex. Neurosci Lett 2011;497:99-103
   PubMed Web of Science ®Google Scholar
• Agostinho FR, Scaini G, Ferreira GK, Effects of olanzapine, fluoxetine, and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res Bull 2009;80:337-40
   PubMed Web of Science ®Google Scholar
• Seager MA, Huff KD, Barth VN, Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004;55:1103-9
   PubMed Web of Science ®Google Scholar
• Perrone JA, Chabla JM, Hallas BH, Weight loss dynamics during combined fluoxetine and olanzapine treatment. BMC Pharmacol 2004;4:27-31
   PubMedGoogle Scholar
• Gossen D, de Suray JM, Vandenhende F, Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002;4:E11
   PubMed Web of Science ®Google Scholar
• Citrome L, Stauffer VL, Chen L, Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009;29:278-83
   PubMed Web of Science ®Google Scholar
• Molden E, Spigset O. Tobacco smoking and drug interactions. Tidsskr Nor Laegeforen 2009;129:632-3
   PubMedGoogle Scholar
• Tamayo JM, Sutton VK, Mattei MA, Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression. An open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009;29:358-61
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese JR, Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
   PubMed Web of Science ®Google Scholar
• Keck PEJ, Corya SA, Altshuler LL, Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry 2005;66:611-16
   PubMed Web of Science ®Google Scholar
• Bertschy F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004;65:1537-45
   PubMed Web of Science ®Google Scholar
• Dube S, Tollefson GD, Thase ME, Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007;9:618-27
   PubMed Web of Science ®Google Scholar
• Benazzi F, Berk M, Frye MA, Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry 2009;70:1424-31
   PubMed Web of Science ®Google Scholar
• Vieta E, Berk M, Wang W, Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009;119:22-7
   PubMed Web of Science ®Google Scholar
• Corya SA, Perlis RH, Keck PEJ, A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006;67:798-806
   PubMed Web of Science ®Google Scholar
• Kemp DE, Ganocy SJ, Brecher M, Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 2011;130:171-9
   PubMed Web of Science ®Google Scholar
• Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011;12:2751-8
   PubMed Web of Science ®Google Scholar
• Perlis RH, Adams D, Fijal B, Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry 2010;71:599-605
   PubMed Web of Science ®Google Scholar
• Brown E, McElroy SL, Keck PEJ, A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-33
   PubMed Web of Science ®Google Scholar
• Brown E, Dunner DL, McElroy SL, Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar depression. Int J Neuropsychopharmacol 2009;12:773-82
   PubMed Web of Science ®Google Scholar
• Houston JP, Fijal B, Heinloth AN, Adams D. Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry Res 2010;175:171-2
   PubMed Web of Science ®Google Scholar
• Degenhardt EK, Jamal HH, Tormey S, Case M. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination. An analysis of 2 adult studies in treatment-resistant depression. J Clin Psychopharmacol 2011;31:337-40
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Thase ME, Osuntokun O, An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009;70:387-96
   PubMed Web of Science ®Google Scholar
• Lipkovich I, Jacobson JG, Caldwell C, Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull 2009;42:23-39
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Brown CH, Hur K, Suicidal thoughts and behavior with antidepressant treatment. Reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:580-7
   PubMed Web of Science ®Google Scholar
• Berghoefer A, Kossmann B, Mueller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996;93:349-54
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Post RM, Leverich GS, Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-8
   PubMed Web of Science ®Google Scholar
• Association AD, Association AP. Endocrinologists AAoC, Obesity NAAftSo. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
   PubMed Web of Science ®Google Scholar
• Dubovsky SL, Dubovsky AN. Psychotropic drug prescriber's survival guide: ethical prescribing in the age of big pharma. W.W. Norton, New York; 2007
   Google Scholar